Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP – the PLRG report

Abstract

Comorbidities impair the prognosis of diffuse large B-cell lymphoma (DLBCL). Type 2 diabetes mellitus (DMT2) increases the risk of other comorbidities, e.g., heart failure (HF). Thus, we hypothesized that pre-existing DMT2 may negatively affect the outcome of DLBCL. To verify this, DLBCL patients treated with (R)-CHOP were enrolled. 469 patients were eligible, with a median age of 57 years; 356 patients had advanced-stage DLBCL. 126 patients had high-intermediate and 83 high-risk international prognostic index (IPI). Seventy-six patients had DMT2, 46 HF; 26 patients suffered from both DMT2 and HF. In the analyzed group DMT2 or HF significantly shortened overall survival (OS) and progression free survival (PFS): the 5-year OS for patients with DMT2 was 64% vs 79% and for those with HF: 49% vs 79%. The 5-year PFS for DMT2 was 50.6% vs 62.5% and for HF 39.4% vs 63.2%. The relapse/progression incidence was comparable between groups; the non-relapse/progression mortality (NRPM) was significantly higher solely in DMT2 patients (5-year NRPM 22.5% vs 8.4%). The risk of death was higher in patients with higher IPI (HR = 1.85) and with DMT2 (HR = 1.87). To conclude, pre-existing DMT2, in addition to a higher IPI and HF, was a negative predictor for OS and PFS. Pre-existing comorbidities create an additional challenge in lymphoma management. First, comorbidities increase the risk of treatment-related complications, and second, treatment itself aggravates their clinical course 1. As a consequence, lymphoma and comorbidities act as competing risks for death in respective patients. In

Risk factors for cardiovascular events and mortality in patients diagnosed with diffuse large B‐cell lymphoma and treated with anthracyclines

“…12 In an analysis by the Polish Lymphoma Research Group of 469 DLBCL patients treated with CHOP or R-CHOP, diabetic patients had a 15% lower 5-year OS. 13 It has been hypothesized…”

TRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma

“…The four selected risk features have also consistently been found to be independently associated with reduced OS in DLBCL. [22][23][24][25] Although further research is certainly warranted, these reports further underpin the predictor selection proposed in this analysis.…”

Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma

“…Other recently reported studies have shown that a diagnosis of type 2 diabetes is associated with worse outcomes in the context of DLBCL [ 46 , 47 ]; however, sex-specific differences have not been previously reported. In this study, a diagnosis of diabetes had a significant negative impact on male OS ( p = 0.004).…”